Ajani, J. A., Kato, K., Yang, F., Wang, Q., Shen, L. (2026). A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps467